Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
67 hedge funds and large institutions have $216M invested in Dicerna Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 7 closing their positions.
256% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 9
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
24% more funds holding
Funds holding: 54 → 67 (+13)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
31% less capital invested
Capital invested by funds: $313M → $216M (-$97.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.6M |
| 2 |
Millennium Management
New York
|
+$7.16M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.36M |
| 4 |
RI
RTW Investments
New York
|
+$5.3M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
-$2.96M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$2.51M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$1.55M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.15M |
| 5 |
JP Morgan Chase
New York
|
-$1.09M |
DRNA Hedge Fund Activity: Q2 2015 in Review
67 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2015, worth a combined $216M — down 31% from $313M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new DRNA positions and 7 closed out — a net gain of 13 holders — while 32 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.6M. The largest seller was ISZO Capital Management, exiting entirely with an estimated $2.96M sold.
- 67 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2015, up from 54 in Q1 2015.
- Funds reported $216M of Dicerna Pharmaceuticals, Inc. stock for Q2 2015, down 31% quarter-over-quarter.
- 20 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2015 and 7 closed out, a net change of +13 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2015 was Fidelity Investments, an estimated $7.6M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2015 was ISZO Capital Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q2 2015.